Ann: US Clinical Trial Results Published, page-18

Day and short-term traders have done what they do, and made a very handsome return on it too I would expect.

For those looking for an investment-grade return on business operations rather than simple trading on volatility, I don't see any compelling reason to leap in immediately.

1) FDA approval for our additional claims in the USA will take some months to obtain.
2) Sales of Mente version 2 beginning in August will take some time to roll through into cash flow, and will take even longer to cover the cost of our initial inventory.

Both buy and sell stacks are very thin indeed!